[1] Roy L,Guilhot J,Krahnke T,et al.Survival advantage from imatinib compared with the combination interferon-plus cytarabine in chronic-phase ehronie myelogenous leukemia:historical comparison between two phase 3 trials[J]. Blood,2006,108(5):1478-1484. [2] 高鑫,刘侠,潘敏. 青少年白血病患者治疗期的生活质量及其影响因素[J]. 中国肿瘤临床与康复,2018,25(9):1065-1068. [3] Baccarani M,Saglio G,Goldman J,et al.Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European Leukemia Net[J]. Blood,2006,108(6):1809-1820. [4] 陈亨,蒋元强,沈云峰,等. 诱导疗法对急性髓系白血病患者临床疗效及生活质量的影响[J]. 中国肿瘤临床与康复,2016,23(11):1328-1330. [5] Jemal A,Siegel R,Xu J,et al.Cancer statistics[J]. CA Cancer J Clin,2010,60(5):277-300. [6] O'brien S,Radich JP,Abboud CN,et al. Chronic myelogenous leukemia,version 1.2014[J]. J Natl Compr Canc Netw,2013,11(11):1327-1340. [7] Tong YQ,Liu B,Zheng HY,et al.BMI-1 autoantibody as a new potential biomarker for cervical carcinoma[J]. PLoS One,2011,6(1 1):e27804. [8] Brien SG,Guilhot F,Goldman JM.Internatinnal randomized study of interferon versus STl57 1(IRIS)7-year follow-up:sustained survival,low rate of transformation and increased rate of major molecular response(MMR)in patients(pts)with newly diagnosed chronic myeloid leukemia in chronic phase treated with imatinib(IM)[J]. Blood,2008,112(11):76. [9] Kantarjian HM,Talpaz M,O’Brien S,et al. Survival benefit with imatinib mesylate versus interferon-based regimens in newly diag-nosed chronic·phase chronic myelogenous leukemia[J]. Blood,2006,108(6):1835-1840. [10] Gugliotta G,Castagnetti F,Apolinari MA,et al.First-line treatment of newly diagnosed elderly patients with chronic myeloid leukemia: current and emerging strategies[J]. Drugs,2014,74(6):627-643. [11] 马永华,张开金,刘桂圆,等. 使用伊马替尼治疗的慢性粒细胞白血病患者的生命质量影响因素分析[J]. 上海交通大学学报(医学版),2016,36(7):1059-1062. [12] O'brien SG,Guilhot F,Larson RA,et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia[J]. N Engl J Med,2003,348(11):994-1004. |